A prospective cohort study of rituximab in the treatment of refractory nephrotic syndrome

A prospective cohort study of rituximab in the treatment of refractory nephrotic syndrome

Objective To explore the efficacy and safety of rituximab (RTX) in the treatment of autoimmune nephropathy manifested as refractory nephrotic syndrome (RNS). Methods A single-center prospective cohort study was conducted on RNS patients treated with RTX between March 2017 and December 2019. The subj...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International urology and nephrology 2022-01, Vol.54 (1), p.121-130
Hauptverfasser: Xu, Jing, Ding, Ying, Wan, Li, Yang, Qinghua, Qu, Zhen
Format: Artikel
Sprache:eng
Schlagworte:
Adult
Aged
Cohort analysis
Cohort Studies
Epidermal growth factor receptors
Female
Glomerular Filtration Rate
Humans
Immunologic Factors - adverse effects
Immunologic Factors - therapeutic use
Immunotherapy
Infections
Kidney diseases
Male
Medical prognosis
Medicine
Medicine & Public Health
Middle Aged
Monoclonal antibodies
Nephrology
Nephrology - Original Paper
Nephropathy
Nephrotic syndrome
Nephrotic Syndrome - drug therapy
Nephrotic Syndrome - physiopathology
Patients
Prospective Studies
Remission
Rituximab
Rituximab - adverse effects
Rituximab - therapeutic use
Survival
Treatment Outcome
Urology
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objective To explore the efficacy and safety of rituximab (RTX) in the treatment of autoimmune nephropathy manifested as refractory nephrotic syndrome (RNS). Methods A single-center prospective cohort study was conducted on RNS patients treated with RTX between March 2017 and December 2019. The subjects were divided into the primary nephropathy (PN) group and the secondary nephropathy (SN) group. Based on the estimated glomerular filtration rate (eGFR) before RTX treatment, the SN group was then divided into the SN-1 group (eGFR ≥ 30 ml/min) and the SN-2 group (eGFR 
ISSN:0301-1623
1573-2584
DOI:10.1007/s11255-021-02860-4